Skip to main
FEMY
FEMY logo

Femasys (FEMY) Stock Forecast & Price Target

Femasys (FEMY) Analyst Ratings

Based on 5 analyst ratings
Strong Buy
Strong Buy 100%
Buy 0%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Femasys Inc. is poised for growth with the anticipated commercialization of FemBloc in Europe, projected to begin in the second half of 2025 or the first half of 2026, thereby creating additional revenue streams. The company has established strategic partnerships with Spanish distributors for FemBloc, indicating strong relationships and a clear path toward market entry following the recent EU approval of the delivery system. Furthermore, promising safety and efficacy results for FemBloc suggest it may offer a superior alternative to existing permanent birth control methods, positioning Femasys favorably within the women's healthcare landscape.

Bears say

Femasys Inc. faces significant risks that contribute to a negative outlook on its stock, including potential safety signals from clinical and preclinical programs, which could impede development. The company also risks lower-than-expected efficacy in its clinical programs, with studies potentially failing to achieve statistical significance, exacerbating competitive pressures from other treatments. Furthermore, the reliance on substantial financing, estimated at ~$80 million needed through 2037 despite a cash runway extending only into mid-2025, poses a challenge to its financial viability and strategic growth.

Femasys (FEMY) has been analyzed by 5 analysts, with a consensus rating of Strong Buy. 100% of analysts recommend a Strong Buy, 0% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Femasys and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Femasys (FEMY) Forecast

Analysts have given Femasys (FEMY) a Strong Buy based on their latest research and market trends.

According to 5 analysts, Femasys (FEMY) has a Strong Buy consensus rating as of Jul 23, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $8.20, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $8.20, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Femasys (FEMY)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.